IRIS Accounts Production v25.4.0.155 06861239 Board of Directors Board of Directors 1.5.24 30.4.25 30.4.25 0 12 false true true false false true true true true false Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 06861239 2024-04-30 06861239 2025-04-30 06861239 2024-05-01 2025-04-30 06861239 2023-04-30 06861239 2023-05-01 2024-04-30 06861239 2024-04-30 06861239 ns15:EnglandWales 2024-05-01 2025-04-30 06861239 ns14:USDollar 2024-05-01 2025-04-30 06861239 ns10:Director1 2024-05-01 2025-04-30 06861239 ns10:Director2 2024-05-01 2025-04-30 06861239 ns10:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 06861239 ns10:MediumEntities 2024-05-01 2025-04-30 06861239 ns10:Audited 2024-05-01 2025-04-30 06861239 ns10:SmallCompaniesRegimeForDirectorsReport 2024-05-01 2025-04-30 06861239 ns10:Medium-sizedCompaniesRegimeForAccounts 2024-05-01 2025-04-30 06861239 ns10:FullAccounts 2024-05-01 2025-04-30 06861239 ns10:OrdinaryShareClass1 2024-05-01 2025-04-30 06861239 ns10:CompanySecretary1 2024-05-01 2025-04-30 06861239 ns10:RegisteredOffice 2024-05-01 2025-04-30 06861239 ns5:CurrentFinancialInstruments 2025-04-30 06861239 ns5:CurrentFinancialInstruments 2024-04-30 06861239 ns5:ShareCapital 2025-04-30 06861239 ns5:ShareCapital 2024-04-30 06861239 ns5:FurtherSpecificReserve2ComponentTotalEquity 2025-04-30 06861239 ns5:FurtherSpecificReserve2ComponentTotalEquity 2024-04-30 06861239 ns5:RetainedEarningsAccumulatedLosses 2025-04-30 06861239 ns5:RetainedEarningsAccumulatedLosses 2024-04-30 06861239 ns5:ShareCapital 2023-04-30 06861239 ns5:RetainedEarningsAccumulatedLosses 2023-04-30 06861239 ns5:FurtherSpecificReserve2ComponentTotalEquity 2023-04-30 06861239 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-04-30 06861239 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-04-30 06861239 ns5:CurrentFinancialInstruments 2024-05-01 2025-04-30 06861239 ns10:OrdinaryShareClass1 2025-04-30

REGISTERED NUMBER: 06861239 (England and Wales)

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025

FOR

CHAMPIONS ONCOLOGY UK LIMITED

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2025

Page |

| Company information | 1 |

| Report of the directors | 2 |

| Report of the independent auditors | 3 |

| Statement of comprehensive income | 6 |

| Balance sheet | 7 |

| Statement of changes in equity | 8 |

| Notes to the financial statements | 9 |

| CHAMPIONS ONCOLOGY UK LIMITED |

COMPANY INFORMATION

FOR THE YEAR ENDED 30 APRIL 2025

| Directors: | David Sidransky

| Joel Ackerman

| Secretary: | Vistra Company Secretaries Limited

| Registered office: | Suite 1, 7th Floor

| 50 Broadway

| London

| SW1H 0BL

| Registered number: | 06861239 (England and Wales)

| Auditors: | Fuller & Roper Limited

| Chartered Accountants and Statutory Auditors

| 12 Old Mills Industrial Estate

| Paulton

| BS39 7SU

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

REPORT OF THE DIRECTORS

FOR THE YEAR ENDED 30 APRIL 2025

The directors present their report with the financial statements of the company for the year ended 30 April 2025.

Principal activity

The principal activity of the company in the year under review was that of a holding company for a branch.

Directors

The directors shown below have held office during the whole of the period from 1 May 2024 to the date of this report.

David Sidransky

Joel Ackerman

Statement of directors' responsibilities

The directors are responsible for preparing the Report of the directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement as to disclosure of information to auditors

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Auditors

The auditors, Fuller & Roper Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board:

Joel Ackerman - Director

28 April 2026

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

CHAMPIONS ONCOLOGY UK LIMITED

Opinion

We have audited the financial statements of Champions Oncology UK Limited (the 'company') for the year ended 30 April 2025 which comprise the Statement of comprehensive income, Balance sheet, Statement of changes in equity and Notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the company's affairs as at 30 April 2025 and of its profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Report of the directors, but does not include the financial statements and our Report of the auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Report of the directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Report of the directors has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

- | the financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit; or

- | the directors were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic report or in preparing the Report of the directors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

CHAMPIONS ONCOLOGY UK LIMITED

Responsibilities of directors

As explained more fully in the Statement of directors' responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures to respond to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis to our opinion.

We have identified and assess the potential risks related to irregularities, including fraud, by:

- Making enquiries of management regarding the compliance with laws and regulations, the detection of and response to the risk of fraud and any knowledge of actual, suspected or alleged fraud. We also discussed the controls in place to mitigate fraud risks or non-compliance with laws and regulations.

- Obtaining an understanding of the legal and regulatory framework in which the company operates. The key laws and regulations are considered to be accounting standards, employment legislation and the Companies Act 2006.

We have responded to risks identified by performing procedures including the following:

- Making enquiries of management concerning actual and potential litigation claims;

- Performing analytical procedures to identify any unusual or unexpected relationships which may indicate risks of misstatement due to fraud;

- Reviewing the financial statement disclosures and testing to supporting documentation; and

- Reviewing payroll records and agreeing to nominal ledger entries.

We have also considered the risk of fraud through management override of controls by:

- Testing a sample of journal entries for appropriateness; and

- Assessing whether the judgements made in making accounting estimates are indicative of potential bias.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the auditors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

CHAMPIONS ONCOLOGY UK LIMITED

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Fuller & Roper Limited (Senior Statutory Auditor)

for and on behalf of Fuller & Roper Limited

Chartered Accountants and Statutory Auditors

12 Old Mills Industrial Estate

Paulton

BS39 7SU

18 May 2026

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

STATEMENT OF COMPREHENSIVE

INCOME

FOR THE YEAR ENDED 30 APRIL 2025

2025 | 2024 |

| Notes | $ | $

TURNOVER | 1,783,479 |  | 2,078,892 |  |

Cost of sales | (305,773 | ) | (369,118 | ) |

GROSS PROFIT | 1,477,706 |  | 1,709,774 |  |

Sales and marketing | (1,184,977 | ) | (1,438,477 | ) |

Administrative expenses | (292,793 | ) | (271,297 | ) |

OPERATING LOSS | 4 | (64 | ) | - |  |

Interest receivable and similar income | 64 |  | - |  |

PROFIT BEFORE TAXATION | - |  | - |  |

Tax on profit | 5 | - |  | - |  |

PROFIT FOR THE FINANCIAL YEAR | - |  | - |  |

OTHER COMPREHENSIVE INCOME | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | - |  | - |  |

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

BALANCE SHEET

30 APRIL 2025

2025 | 2024 |

| Notes | $ | $

CURRENT ASSETS

Debtors | 6 | 34,914 |  | 14,790 |  |

Cash at bank | 66,122 |  | 62,466 |  |

101,036 |  | 77,256 |  |

CREDITORS

Amounts falling due within one year | 7 | (671,549 | ) | (659,401 | ) |

NET CURRENT LIABILITIES | (570,513 | ) | (582,145 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | (570,513 | ) | (582,145 | ) |

CAPITAL AND RESERVES

Called up share capital | 8 | 149 |  | 149 |  |

Employee Share Option | 9 | 37,112 |  | 25,480 |  |

Retained earnings | 9 | (607,774 | ) | (607,774 | ) |

SHAREHOLDERS' FUNDS | (570,513 | ) | (582,145 | ) |

The financial statements were approved by the Board of Directors and authorised for issue on 28 April 2026 and were signed on its behalf by:

Joel Ackerman - Director

David Sidransky - Director

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 APRIL 2025

Called up | Employee |  |

share | Retained | Share | Total |

capital | earnings | Option | equity |

| $ | $ | $ | $

Balance at 1 May 2023 | 149 |  | (607,774 | ) | 12,075 |  | (595,550 | ) |

Changes in equity

Profit for the year | - |  | - |  | - |  | - |  |

Employee share option scheme | - |  | - |  | 13,405 |  | 13,405 |  |

Balance at 30 April 2024 | 149 |  | (607,774 | ) | 25,480 |  | (582,145 | ) |

Changes in equity

Profit for the year | - |  | - |  | - |  | - |  |

Employee share option scheme | - |  | - |  | 11,632 |  | 11,632 |  |

Balance at 30 April 2025 | 149 |  | (607,774 | ) | 37,112 |  | (570,513 | ) |

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2025

1. | STATUTORY INFORMATION

| Champions Oncology UK Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The functional and presentational currency of the company is the US Dollar ($) and these financial statements have been rounded to the nearest dollar.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

| • | the requirements of Section 7 Statement of Cash Flows;

| • | the requirement of paragraph 3.17(d);

| • | the requirements of paragraphs 11.42, 11.44, 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);

| • | the requirements of paragraphs 12.26, 12.27, 12.29(a), 12.29(b) and 12.29A;

| • | the requirements of paragraphs 26.18(b), 26.19 to 26.21 and 26.23.

| - This information is included in the consolidated financial statements of Champions Oncology, Inc. These financial statements can be obtained from www.championsoncology.com

| Turnover

| Turnover is derived based on the agreement in place, on a cost reimbursement basis.

| Financial instruments

| The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments.

| Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

| Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Classification of financial liabilities

| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.

| Basic financial liabilities

| Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price.

| Debtors

| Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fairvalue, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

| Creditors

| Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

| Cash and cash equivalents

| Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date ofacquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 APRIL 2025

2. | ACCOUNTING POLICIES - continued

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into US Dollar at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into US Dollar at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to the income statement in the period to which they relate.

| Going concern

| Although the balance sheet is showing a net current liability position the financial statements have been prepared on the going concern basis. The directors have received assurances from the parent company that all necessary funding will be made available for the company to continue as a going concern.

| Share based payments

| The cost and corresponding increase in equity in respect of equity-settled share-based payment transactions with employees are measured by reference to the fair value of equity instruments issued at the date of grant. Amounts are expensed on a straight line basis over the vesting period based on the estimate of shares that will eventually vest and adjusted for the effect of non market-based vesting conditions. The cost and fair value of the liability incurred in respect of cash-settled transactions is measured using an appropriate option pricing model with changes in fair value recognised in profit or loss for the period. Further detail is provided in note 11.

3. | EMPLOYEES AND DIRECTORS

|  | 30/4/25 |  | 30/4/24 |  |

|  | $ |  | $ |  |

| Wages and Salaries |  | 1,255,102 |  | 1,597,735 |  |

| Social security |  | 223,372 |  | 259,361 |  |

| Other pension costs |  | 25,280 |  | 34,574 |  |

| The average number of employees during the year was as follows:

|  | 30/4/25 |  | 30/4/24 |  |

| Employees |  | 10 |  | 12 |  |

2025 | 2024 |

| $ | $

| Directors' remuneration | - |  | - |  |

4. | OPERATING LOSS

| The operating profit is stated after charging /(crediting):

|  | 30/4/25 |  | 30/4/24 |  |

|  | $ |  | $ |  |

| Foreign exchange differences |  | 1,161 |  | 1,281 |  |

| Auditor's remuneration |  | 6,888 |  | 6,675 |  |

5. | TAXATION

| No liability to UK corporation tax arose for the year ended 30 April 2025 nor for the year ended 30 April 2024, as the company's taxable profit for each year is $nil.

CHAMPIONS ONCOLOGY UK LIMITED (REGISTERED NUMBER: 06861239) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 APRIL 2025

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

| $ | $

| Other debtors | 29,770 |  | 11,312 |  |

| Prepayments | 5,144 |  | 3,478 |  |

34,914 |  | 14,790 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

| $ | $

| Trade creditors | 5,370 |  | - |  |

| Amounts owed to group | 579,682 |  | 577,402 |  |

| Accrued expenses | 86,497 |  | 81,999 |  |

671,549 |  | 659,401 |  |

| Amounts owed to group undertakings are unsecured, interest free and repayable on demand.

8. | CALLED UP SHARE CAPITAL

| Allotted and issued:

| Number: | Class: | Nominal | 2025 | 2024 |

value: |  | $ | $

| 100 | Ordinary | £1 | 149 |  | 149 |  |

| Called up share capital represents the nominal value of the shares issued.

9. | RESERVES

| Retained Earnings

| Retained earnings represents cumulative profits or losses, net of dividends paid and other adjustments

| Employee Share Option Reserve

| The employee share option reserve represents the cumulative amounts charges to profit or loss on respect of employee share option agreements.

10. | ULTIMATE CONTROLLING PARTY

| The company is a wholly owned subsidiary of Champions Oncology Inc, a company incorporated in Delaware, USA and listed on the NASDAQ stock exchange, with registered office at 1 University Plaza, Suite 307, Hackensack, New Jersey 07601, USA.

| The Directors consider the ultimate controlling party to be Battery Ventures IX L.P. a limited partnership incorporated in Delaware, USA.

11. | SHARE-BASED PAYMENT TRANSACTIONS

| During the year, 3,500 options to purchase shares in the parent company, Champions Oncology Inc, were granted to employees of the company under share-based payment arrangements at an exercise price of $4.25 per share. The total expense recognised during the year in respect of share-based payments is $11,632 (2024 - $13,405).